Literature DB >> 15491800

The myth of the biotech revolution.

Paul Nightingale1, Paul Martin.   

Abstract

The existence of a medicinal 'biotech revolution' has been widely accepted and promoted by academics, consultants, industry and government. This has generated expectations about significant improvements in the drug discovery process, healthcare and economic development that influence a considerable amount of policy-making. Here we present empirical evidence, from a variety of indicators, that shows that a range of outputs have failed to keep pace with increased research and development spending. Rather than producing revolutionary changes, medicinal biotechnology is following a well-established pattern of slow and incremental technology diffusion. Consequently, many expectations are wildly optimistic and over-estimate the speed and extent of the impact of biotechnology, suggesting that the assumptions underpinning much contemporary policymaking need to be rethought.

Mesh:

Substances:

Year:  2004        PMID: 15491800     DOI: 10.1016/j.tibtech.2004.09.010

Source DB:  PubMed          Journal:  Trends Biotechnol        ISSN: 0167-7799            Impact factor:   19.536


  14 in total

1.  Genetics, Big Brother and the GP.

Authors:  Tom Shakespeare
Journal:  Br J Gen Pract       Date:  2006-03       Impact factor: 5.386

Review 2.  Therapeutic misconception: hope, trust and misconception in paediatric research.

Authors:  Simon Woods; Lynn E Hagger; Pauline McCormack
Journal:  Health Care Anal       Date:  2014-03

3.  Risk assessment and communication tools for genotype associations with multifactorial phenotypes: the concept of "edge effect" and cultivating an ethical bridge between omics innovations and society.

Authors:  Vural Ozdemir; Guilherme Suarez-Kurtz; Raphaëlle Stenne; Andrew A Somogyi; Toshiyuki Someya; S Oğuz Kayaalp; Eugene Kolker
Journal:  OMICS       Date:  2009-02

4.  Encounters with medical professionals: a crisis of trust or matter of respect?

Authors:  Nina Hallowell
Journal:  Med Health Care Philos       Date:  2008-07-30

5.  Translational research policies: disruptions and continuities in biomedical innovation systems in Austria, Finland and Germany.

Authors:  Etienne Vignola-Gagné; Elina Rantanen; Daniel Lehner; Bärbel Hüsing
Journal:  J Community Genet       Date:  2012-12-29

6.  Where are you going, where have you been: a recent history of the direct-to-consumer genetic testing market.

Authors:  Pascal Borry; Martina C Cornel; Heidi C Howard
Journal:  J Community Genet       Date:  2010-10-08

Review 7.  Cell injury, retrodifferentiation and the cancer treatment paradox.

Authors:  José Uriel
Journal:  Tumour Biol       Date:  2015-09-07

8.  "You are our only hope": trading metaphorical "magic bullets" for stem cell "superheroes".

Authors:  Lawrence Burns
Journal:  Theor Med Bioeth       Date:  2009

9.  Rise and demise of bioinformatics? Promise and progress.

Authors:  Christos A Ouzounis
Journal:  PLoS Comput Biol       Date:  2012-04-26       Impact factor: 4.475

10.  BNDB - the Biochemical Network Database.

Authors:  Jan Küntzer; Christina Backes; Torsten Blum; Andreas Gerasch; Michael Kaufmann; Oliver Kohlbacher; Hans-Peter Lenhof
Journal:  BMC Bioinformatics       Date:  2007-10-02       Impact factor: 3.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.